Tempest Therapeutics Inks Global Option for Senlang In Vivo CAR-T, $10—$14M Fees, 6% Royalty
Tempest Therapeutics entered an exclusive collaboration, option and license agreement to access Heibei Senlang Biotechnology’s in vivo CAR-T technology. The four-month option, exercisable for about $447,000, would grant Tempest an exclusive, sublicensable license worldwide excluding Greater China…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.